Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication. (00:32) Could you provide us with a little bit of information about yourself and your background? (01:18) Can you start with a brief overview of the assay? (02:13) Which patients should have this testing and when should it be performed? (03:21) Are there alternative test options available and how do those compare with the folate receptor alpha assay? (03:57) How are the results used in patient care?